1. Clinical & Scientific Overview
Ketamine Hydrochloride (TIP-MED-000525, Reference Code [R-06]) is classified under
Anaesthetics & Critical Care Medicines as a Dissociative General Anaesthetic (NMDA Receptor Antagonist).
Within the Indian regulatory and compendial framework, it is governed under Schedule X (Drugs Rules, 1945) & Psychotropic Substance.
Aneket (Neon Laboratories), Ketalar (Pfizer / Parke-Davis), Ketmin (Themis Medicare)
Injection: 10 mg/mL (10 mL vial), 50 mg/mL (2 mL and 10 mL vials)
Statutory Restriction, High-Alert & Dispensing Safeguards
Indian Regulatory & Statutory Control Basis: Schedule X (Drugs Rules, 1945) & Psychotropic Substance
High-Alert Clinical Risk, Dependence & Narrow Therapeutic Index Warnings: Schedule X mandatory regulatory control due to high diversion and recreational abuse potential; causes emergence delirium/hallucinations (mitigated by midazolam), sympathetic surge (tachycardia, hypertension), and ulcerative cystitis with chronic misuse.
Mandatory Dispensing Register & Institutional Custody Protocol: Schedule X prescription must be retained for 2 years in original; institutional anaesthesia custody only.
3. Mechanism of Action & Pharmacodynamics
Non-competitive antagonist at the phencyclidine site of NMDA (N-methyl-D-aspartate) glutamate receptors, functionally dissociating thalamocortical and limbic systems while preserving airway reflexes and sympathetic tone.
4. Therapeutic Indications & Evidence-Supported Uses
- Diagnostic and surgical induction/maintenance anaesthesia
- Refractory status asthmaticus and procedural sedation in emergency medicine
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist-Supervised Educational Reference Summary: Dosing of Ketamine must be individualised by a qualified specialist according to clinical indication, organ function, and institutional protocol (Injection: 10 mg/mL (10 mL vial), 50 mg/mL (2 mL and 10 mL vials)).
Administration & Meal Timing: Routes: Intravenous, Intramuscular. Schedule X prescription must be retained for 2 years in original; institutional anaesthesia custody only.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Exhibits dissociative general anaesthetic (nmda receptor antagonist) pharmacokinetic disposition; verify baseline renal and hepatic clearance and check for active or prolonged-half-life metabolites before repeat dosing.
Hepatic Phase I (CYP450) and/or Phase II conjugation or specific non-renal clearance as detailed in clinical warnings.
Verify eGFR / CrCl before initiation; see specific metabolite and renal clearance notes above.
Assess baseline Child-Pugh status and hepatic transaminases prior to therapy.
7. Contraindications, Precautions & High-Risk Warnings
- Known severe hypersensitivity to Ketamine or formulation excipients
- Unsupervised outpatient self-administration or dispensing without mandatory statutory prescription verification
- Specific clinical contraindications detailed under High-Alert Warnings & Statutory Restrictions
Key Clinical Precautions: Schedule X mandatory regulatory control due to high diversion and recreational abuse potential; causes emergence delirium/hallucinations (mitigated by midazolam), sympathetic surge (tachycardia, hypertension), and ulcerative cystitis with chronic misuse.
8. Adverse Effects Profile
- Schedule X mandatory regulatory control due to high diversion and recreational abuse potential; causes emergence delirium/hallucinations (mitigated by midazolam), sympathetic surge (tachycardia, hypertension), and ulcerative cystitis with chronic misuse.
- Dose-dependent target-organ pharmacodynamic effects requiring clinical observation
- Schedule X mandatory regulatory control due to high diversion and recreational abuse potential; causes emergence delirium/hallucinations (mitigated by midazolam), sympathetic surge (tachycardia, hypertension), and ulcerative cystitis with chronic misuse.
- High-alert toxicity, dependence/diversion risk, or severe organ-specific adverse events if administered outside protocol
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Schedule X mandatory regulatory control due to high diversion and recreational abuse potential; causes emergence delirium/hallucinations (mitigated by midazolam), sympathetic surge (tachycardia, hypertension), and ulcerative cystitis with chronic misuse.
- Review all concomitant CNS depressants, QTc-prolonging agents, nephrotoxins, or CYP450 modulators prior to dispensing.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Schedule X prescription must be retained for 2 years in original; institutional anaesthesia custody only.
Pharmacist Patient Counselling Points:
- Schedule X prescription must be retained for 2 years in original; institutional anaesthesia custody only.
- Must be used strictly under direct medical supervision; never share prescription medicines or alter the prescribed dose.
Storage, Stability & Dispensing Safeguards: Schedule X prescription must be retained for 2 years in original; institutional anaesthesia custody only.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Drugs and Cosmetics Act, 1940 & Rules, 1945 (Schedule H / H1 / X); NDPS Act, 1985 & Essential Narcotic Drugs (END) Notification; Indian Pharmacopoeia (IP) & National Formulary of India (NFI).
Official Verification Portals: CDSCO — Drugs & Cosmetics Act and Rules (Schedules H, H1, X) • Department of Revenue — Narcotic Drugs and Psychotropic Substances (NDPS) Act • Indian Pharmacopoeia Commission (IPC) — National Formulary of India
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.